跳至主要内容
临床试验/NCT07040774
NCT07040774招募中不适用

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Imagine Institute47 个研究点 分布在 11 个国家目标入组 500 人开始时间: 2025年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
500
试验地点
47
主要终点
Characterizing disease progression in pediatric and adult patients with type I interferonopathies

研究概览

简要总结

Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.

Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.

In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.

The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.

The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • Genetically confirmed patient with type I interferonopathy
  • Patient affiliated to a social security scheme or beneficiary of such a scheme.

排除标准

  • - Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.

研究组 & 干预措施

Patients

Patients with genetically confirmed type I interferonopathy

结局指标

主要结局

Characterizing disease progression in pediatric and adult patients with type I interferonopathies

时间窗: 2025-2045

Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.

次要结局

  • Identifing and characterising genotype-specific immunological factors(2025-2045)
  • Research of biomarkers for diagnosis, prognosis and monitoring of disease activity(2025-2045)
  • Monitoring of treatment response according to phenotype and genotype(2025-2045)

研究者

发起方
Imagine Institute
申办方类型
Other
责任方
Sponsor

研究点 (47)

Loading locations...

相似试验